

출혈위험이 높은 환자에게 지속적 신대체요법 처방시 후탄의 역할

성균관의대 삼성서울병원 신장내과

백나나 · 염지연 · 장혜련 · 허우성 · 김윤구 · 김대중 · 오하영 · 이정은

The Role of Nafamostat Mesilate in Continuous Renal Replacement Therapy among Patients at High Risk of Bleeding

Na Na Baek, Ji Youn Youm, Hye Ryoum Jang, Wooseong Huh, Yoon-Goo Kim
Dae Joong Kim, Ha Young Oh, Jung Eun Lee

Sungkyunkwan University School of Medicine Samsung Medical Center
Department of Medicine Division of Nephrology

Continuous renal replacement therapy (CRRT) has emerged as the preferred dialysis modality for critically ill patients with acute kidney injury. The objectives of this retrospective study were to assess the effect of nafamostat on circuit patency of CRRT and the safety regarding bleeding complications in patients at high risk of bleeding. We conducted a retrospective study of 243 CRRT patients at high risk of bleeding. We started CRRT without anticoagulation and nafamostat was used if hemofilter lifespan was less than 12 h. The average hemofilter lifespan was measured before and after drug infusion to evaluate the efficacy of nafamostat. The frequency and number of red blood cell were measured to assess the safety of nafamostat. Of the 243 patients, 62 (25.5%) received nafamostat infusion. In nafamostat group, the hemofilter lifespan was lengthened from 10.2 (7.5–13.0) h to 19.8 (12.6–26.6) h after drug infusion ($p < 0.001$). The hemofilter lifespan was 27.5 (17.5–38.2) h in anticoagulation-free group. The frequency of red blood cell transfusion during CRRT did not differ between the nafamostat group and the anticoagulation-free group (71% vs. 70%, $p = \text{NS}$). The median number of red blood cell units transfused per CRRT day was also not different between the two groups [0.7 (0.5–1.0) units/day vs. 0.7 (0.4–1.1) units/day; $p = \text{NS}$]. The use of nafamostat in patients at high risk of bleeding who require CRRT effectively lengthened the filter survival time without an increase in red blood cell transfusion. However, 74.5% of patients at high risk of bleeding maintained an acceptable CRRT hemofilter lifespan without circuit anticoagulation.

Key Words: 지속적신대체요법, 후탄, 급성신부전
CRRT, Nafamostat mesilate, AKI




Fig. 1. Numbers of patients who received CRRT during the study period.




Fig. 2. Hemofilter lifespan before and after nafamostat infusion in the nafamostat group.